Fallopian Tube Clear Cell Adenocarcinoma
Associated Genetic Biomarkers
NCI Definition: A rare adenocarcinoma of the fallopian tube composed of malignant glandular epithelium containing clear cells. 
There are 11 clinical trials for fallopian tube clear cell adenocarcinoma, of which 10 are open and 1 is completed or closed. Of the trials that contain fallopian tube clear cell adenocarcinoma as an inclusion criterion, 2 are phase 1 (2 open), 4 are phase 1/phase 2 (4 open), 4 are phase 2 (3 open), and 1 is phase 3 (1 open).
BRCA1, BRCA2, and ARID1A are the most frequent gene inclusion criteria for fallopian tube clear cell adenocarcinoma clinical trials .
Paclitaxel, carboplatin, and avb-s6-500 are the most common interventions in fallopian tube clear cell adenocarcinoma clinical trials.
Significant Genes in Fallopian Tube Clear Cell Adenocarcinoma
POLE is an inclusion eligibility criterion in 1 clinical trial for fallopian tube clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE status and fallopian tube clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.